A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors - Wikidata - awgldk - TriplyDB

A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors

A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors

http://www.wikidata.org/entity/Q28304273

about

Targeting Cell Survival Proteins for Cancer Cell Death Heat shock protein 90 targeting therapy: state of the art and future perspective Hsp90: A New Player in DNA Repair?Maximizing the Therapeutic Potential of HSP90 Inhibitors Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers Targeting the adaptive molecular landscape of castration-resistant prostate cancer Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer Co-Crystalization and In Vitro Biological Characterization of 5-Aryl-4-(5-Substituted-2-4-Dihydroxyphenyl)-1,2,3-Thiadiazole Hsp90 Inhibitors C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances Regulation and function of the human HSP90AA1 gene The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage 19-substituted benzoquinone ansamycin heat shock protein-90 inhibitors: biological activity and decreased off-target toxicity.Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013.Getting folded: chaperone proteins in muscle development, maintenance and disease.Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors.Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions Inhibition of heat shock protein 90 alleviates steatosis and macrophage activation in murine alcoholic liver injury.A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.Hsp90 molecular chaperone inhibitors: are we there yet?Treatment of Bone Tumors Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.Inhibition of heat shock protein (molecular weight 90 kDa) attenuates proinflammatory cytokines and prevents lipopolysaccharide-induced liver injury in mice.HSP90 inhibitors decrease AID levels and activity in mice and in human cells.Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors.Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells.CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.In vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment.Hypoxia attenuates Hsp90 inhibitor 17-DMAG-induced cyclin B1 accumulation in hepatocellular carcinoma cells.Molecular targets and mechanisms of radiosensitization using DNA damage response pathways.Potent antitrypanosomal activities of heat shock protein 90 inhibitors in vitro and in vivo.Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization.A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB.Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells.Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90 Chemical signatures and new drug targets for gametocytocidal drug development.Hsp90 inhibition protects against inherited retinal degeneration.

P2860

Q26765447-4F6FA796-014A-4455-A828-9B2B02E82BE0 Q26776302-36D601D5-512D-4B11-9D11-DA1C8989A813 Q26778944-BDBD1835-B29C-4CDF-A309-C32B47EA9858 Q26798318-8D64878F-82F8-48AD-BB83-62ABE9F5ACCC Q27022514-FF6DDE5A-D4BE-4067-A75B-73AB8465B0FA Q27022821-D91987D7-DA97-4203-8FF1-B387BE5849FA Q27026128-BF97C966-75E6-48A2-9C02-6581FB3E1E5B Q27673253-E1E4EFD5-976B-4500-B0EC-0D198A017E9B Q28271643-AA43ECB6-CA68-46D6-9288-6A57A86E97A6 Q28646043-87F7FB1D-A450-48CF-89AC-598079760BDC Q28730558-AF1C02CB-D164-4C84-8622-2D6E15EDF1BE Q33584583-12249116-50B8-40A8-A62E-8EC12FFF4E19 Q34038664-96719C99-BCA4-4328-ABCB-EFB9C58B2373 Q34055646-C9B9AD30-60C3-4E1A-9215-DD186B82FE67 Q34085148-E826E814-B026-43C0-92F6-482A1AA7F790 Q34164027-C01C8A9C-2F60-4FD2-AE53-A63A5DA91812 Q34216745-A98FDA2C-74EA-45CE-A42A-417D109F542B Q34570770-85029695-504C-4B64-8834-E12CA225CE91 Q34636437-4951F6FF-DD8A-4FDB-9F37-BA6A1CDA758F Q35655105-BBF424E2-C836-4714-BAFD-8D3DF7323656 Q35740708-9DDC760F-1B99-454C-9202-1BA630ADB42B Q35823157-A1C3B5E6-9947-4FD5-B653-97F28D0966E2 Q35849973-CFEB6376-E41A-4EFD-B350-D1DC7DD362CA Q35930087-9B8334D4-FF88-4668-8256-E1B7FA01C75C Q35952172-54BE8262-8AB3-4B29-86A4-030C9AA3E027 Q36060751-A081869B-5F2B-42B1-95E9-088B497E74D1 Q36074307-0829C4FE-7865-41DA-8C09-404E621B1C90 Q36442900-3742FD94-D4F2-44AB-9CF5-61FE80C8609F Q36465517-7F1B55BF-4969-4BDD-A6F9-D7DB85CF6BE6 Q36647014-1A40222B-F412-46D6-A214-F84D238FA8C5 Q36674083-51929DD4-8A84-416C-8D44-761379D60A2D Q36792626-E81DDE0A-F5F9-4933-B776-5A1A7A38B1A6 Q36974927-7ABE566C-34DF-4BB2-BEA6-437261AF23B4 Q37055162-04763923-EFCA-41CF-A890-FA1A12C05DB6 Q37168481-603A0904-90CB-40C7-B581-0E8728DB46B4 Q37245887-55694B53-0ADD-4BDE-B9DE-FB230D0E9FEF Q37286051-60BD4D49-B9EC-4C5E-9F2E-BF980AEA44E7 Q37293806-408996F5-8582-41F1-801C-4B1D057175A8 Q37489274-DBABED7C-61DF-47F4-A953-310C95D30C39 Q37649115-1A18F21C-3A67-46B6-9729-97DCA38ADDBA

P2860

A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors

http://www.wikidata.org/entity/Q28304273

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A phase I study of the heat sh ...... nts with advanced solid tumors

@ast

A phase I study of the heat sh ...... nts with advanced solid tumors

@en

A phase I study of the heat sh ...... nts with advanced solid tumors

@nl

type

label

A phase I study of the heat sh ...... nts with advanced solid tumors

@ast

A phase I study of the heat sh ...... nts with advanced solid tumors

@en

A phase I study of the heat sh ...... nts with advanced solid tumors

@nl

prefLabel

A phase I study of the heat sh ...... nts with advanced solid tumors

@ast

A phase I study of the heat sh ...... nts with advanced solid tumors

@en

A phase I study of the heat sh ...... nts with advanced solid tumors

@nl

P1433

Q28304273-C3691023-BADB-4D8D-895E-E7935A6ACB0B

P1476

Q28304273-A7EC95F5-A282-4CAB-B9CF-FD127506FE8A

P2093

Q28304273-17C92325-95CB-49C8-8FED-55F306C10F86

Q28304273-21D2ED08-0F6D-4155-AF16-3AAACC7F3D98

Q28304273-2E603621-9101-4659-9775-41C6BBD29EA1

Q28304273-350822B8-85FF-465E-994D-09C9129C053F

Q28304273-3BFAE29D-3B4D-402A-AD4B-C9B2A1BD1B7E

Q28304273-5DA1F69E-87BB-42E4-86A2-83B38BAAD5A1

Q28304273-70C0BA07-432E-42C0-A8D2-8F27F86A5FCF

Q28304273-7C1420CD-F449-4B0A-B7C3-B74D18FA085C

Q28304273-81C7F2CB-8B73-4093-AD12-33B94F3FDA0B

Q28304273-9467C429-D243-41C4-B931-0A30AA8708ED

P2860

Q28304273-01BEA09F-7E45-4DD8-8565-B3AC682A6EF7

Q28304273-0E4D11C5-74A2-4DCC-A7B4-7FD921EA32C2

Q28304273-0E7903E7-2F1D-4A08-B235-05ED15AA3664

Q28304273-133FD407-1FAD-4714-ABB5-B17A0565DA4B

Q28304273-14DAEE0A-7D6F-46ED-A74B-38B31410681D

Q28304273-164B8A57-2C55-414B-920C-1CC6D2668519

Q28304273-185C94C2-111A-477B-9FED-E7C369E3B250

Q28304273-1F9444AD-C849-4362-9498-EB33D10D7A2A

Q28304273-28486A98-3140-40B5-8AE7-E3BCD0419837

Q28304273-2D99EDFF-654E-40C7-94AE-9CC30FBCCCF4

P304

Q28304273-6AF79058-EB8B-4AF7-B22E-8260C6CF734A

P31

Q28304273-06F5CCF9-8E35-4684-A4D5-364916CEA1BD

P3181

Q28304273-18CD93BB-DF8F-42EA-96E8-1382172D04AD

P356

Q28304273-FE8E1576-8023-41DE-8F39-A0BC29B5E216

P407

Q28304273-77F0E1EE-D740-40EC-80AC-3AD898A73031

P433

Q28304273-F709DE3B-8A74-43DA-B9EF-840584316954

P478

Q28304273-22384B96-0A27-449C-B45E-21ED5AEE9C66

P50

Q28304273-55BF75B6-D819-4B4E-B323-42F8230BC93F

P577

Q28304273-995EC7FA-6C75-4915-B88E-DA6BAE202279

P698

Q28304273-CD6B9A69-DEBE-477C-B300-2CB6AD8079D3

P921

Q28304273-93663394-4526-4607-858F-17F69D7FAE00

Q28304273-A4605E7F-1E23-4E89-8F1D-700621DDAF54

P932

Q28304273-654EE1DE-F891-490F-A88E-4C0419EE9BD6

P3181

P356

1078-0432.CCR-10-1927

P1433

Clinical Cancer Research

P1476

A phase I study of the heat sh ...... nts with advanced solid tumors

@en

P2093

Anna Zetterlund

http://www.w3.org/2001/XMLSchema#string

Anthea Hardcastle

http://www.w3.org/2001/XMLSchema#string

Belle Roels

http://www.w3.org/2001/XMLSchema#string

Florence Raynaud

http://www.w3.org/2001/XMLSchema#string

Heidi Peachey

http://www.w3.org/2001/XMLSchema#string

Hendrik-Tobias Arkenau

http://www.w3.org/2001/XMLSchema#string

Ian Judson

http://www.w3.org/2001/XMLSchema#string

Javier Moreno-Farre

http://www.w3.org/2001/XMLSchema#string

Johan S de Bono

http://www.w3.org/2001/XMLSchema#string

Martin M Eatock

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90

Hsp90 isoforms: functions, expression and clinical importance

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models

Targeting the dynamic HSP90 complex in cancer

Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress

HSP90 and the chaperoning of cancer

Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90.

P304

1561-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3052586

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1078-0432.CCR-10-1927

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21278242

http://www.w3.org/2001/XMLSchema#string

P921

P932

3060938

http://www.w3.org/2001/XMLSchema#string